Talphera, Inc. ( (TLPH) ) has released its Q4 earnings. Here is a breakdown of the information Talphera, Inc. presented to its investors.
Talphera, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative therapies for use in medically supervised settings, with a lead product candidate, Niyad™, being studied as an anticoagulant for the extracorporeal circuit.
In its latest earnings report, Talphera announced a significant reduction in the patient size for its NEPHRO CRRT study, following approval from the FDA, and secured a private placement financing of up to $14.8 million to support the study’s completion by the end of 2025.
Key financial highlights include a decrease in net loss from continuing operations to $1.9 million in the fourth quarter of 2024, compared to $4.5 million in the same period of 2023, driven by changes in warrant liability valuation. The company also reported a reduction in combined R&D and SG&A expenses, attributed to lower personnel and administrative costs.
Looking ahead, Talphera remains optimistic about completing the NEPHRO CRRT study by the end of 2025, supported by the recent financing and strategic study adjustments. The company anticipates cash operating expenses for 2025 to be in the range of $18 million to $19 million, including costs related to the NEPHRO study.